中国P站

Gut microbiota; Obesity; Metabolic syndrome; Dysbiosis; Short-Chain Fatty Acids; Prebiotics; Probiotics; Fecal Microbiota Transplantation; Gut-brain axis; Inflammation

Introduction

The escalating global prevalence of obesity and metabolic syndrome underscores the urgent need to understand their intricate etiologies. Emerging research highlights the indispensable role of the gut microbiota as a central modulator in these complex conditions [1].

This microbial community profoundly influences host physiology by impacting energy metabolism, systemic inflammation, and the integrity of the gut barrier. Key mechanisms elucidated involve the production of Short-Chain Fatty Acids (SCFAs), the modulation of bile acid metabolism, and the activity of bacterial lipopolysaccharides, all of which contribute to the metabolic landscape [1].

The dysbiosis, or imbalance, within the gut microbiome, is increasingly recognized as a significant contributor to chronic low-grade inflammation, a well-established hallmark of obesity [2].

Here, specific microbial taxa and their diverse metabolites act as crucial intermediaries, orchestrating host immune responses and fine-tuning energy metabolism. Understanding these molecular interactions opens up new and promising avenues for targeted therapeutic intervention [2].

A strong and consistent association exists between alterations in the gut microbiota composition—often termed dysbiosis—and the development of obesity. Gut microbes exert considerable influence over host metabolism, dictating processes like nutrient extraction efficiency, the intricate regulation of energy homeostasis, and the sophisticated modulation of immune responses [3].

Recognizing these fundamental connections, researchers are actively exploring a range of therapeutic strategies explicitly designed to target the gut microbiota. These include strategic dietary modifications, the introduction of beneficial live microorganisms through probiotics, the selective feeding of beneficial bacteria via prebiotics, and more advanced interventions like Fecal Microbiota Transplantation (FMT) [3].

It is also clear that dietary choices themselves wield a profound impact, acting as a pivotal factor in shaping the gut microbiota's composition and function, which in turn significantly influences the risk of obesity and metabolic syndrome [4].

Different dietary patterns can dramatically reshape the microbial ecosystem, altering how the host harvests energy, modulating insulin sensitivity, and influencing the inflammatory cascades that underpin these conditions [4].

A deeper dive into the metabolic outputs of the gut microbiota reveals the critical role of Short-Chain Fatty Acids (SCFAs) as potent mediators in the context of obesity [5].

SCFAs, primarily acetate, propionate, and butyrate, are end-products of microbial fermentation of dietary fibers. These molecules exert multifaceted effects on the host, influencing energy metabolism, regulating feelings of satiety, bolstering the integrity of the gut barrier, and modulating inflammatory processes. Given their wide-ranging metabolic impact, SCFAs represent compelling potential therapeutic targets for comprehensive obesity management [5].

Beyond dietary and microbial metabolite interventions, more direct approaches like Fecal Microbiota Transplantation (FMT) are gaining traction as a promising therapeutic strategy to combat obesity. The rationale behind FMT centers on its ability to intentionally reshape a dysbiotic gut microbiome, replacing an unhealthy microbial community with one derived from a healthy donor [6].

Preclinical and clinical studies are actively reviewing the evidence for FMT’s effectiveness, observing its measurable effects on weight loss, improvements in various metabolic parameters, and favorable shifts in gut microbial composition in obese individuals [6].

Furthermore, dietary interventions encompassing prebiotics, probiotics, and synbiotics are actively investigated for their utility in obesity management [7].

These interventions are designed to favorably modulate the existing gut microbiota, fostering a healthier microbial balance. Such modulation leads to tangible improvements in overall metabolic health, facilitates effective weight management, and contributes to a reduction in systemic inflammation. These benefits are often mediated through mechanisms like enhanced SCFA production and strengthened gut barrier function [7].

The intricate bidirectional communication between the gut microbiome and the brain, known as the gut microbiota-brain axis, is another significant regulatory pathway in obesity [8].

This axis plays a crucial role in influencing critical physiological processes such as appetite regulation, the induction of satiety, overall energy expenditure, and even mood. Understanding this axis provides valuable insights into potential mechanisms driving weight gain and offers novel strategies for obesity management that target this complex neuro-microbial dialogue [8].

A comprehensive review of various gut microbiota-targeted therapies for obesity and metabolic syndrome critically evaluates the current evidence for dietary interventions, probiotics, prebiotics, synbiotics, Fecal Microbiota Transplantation (FMT), and pharmacological approaches, discussing their underlying mechanisms, observed clinical efficacy, and future potential [9].

Compounding these adult-onset factors, evidence also points to a crucial link between early-life gut microbiota composition and the subsequent risk of obesity development. Early-life factors such as the mode of birth, infant feeding practices, and exposure to antibiotics significantly shape the initial development of the infant microbiome, thereby influencing long-term metabolic programming and ultimately, susceptibility to weight gain [10].

Description

The intricate relationship between the gut microbiota and host health has become a focal point in understanding complex metabolic disorders like obesity and metabolic syndrome. At its core, the gut microbiome profoundly influences energy metabolism, gut barrier integrity, and inflammatory pathways, which are all critical factors in the development and progression of these conditions [1]. Dysbiosis, an imbalance in the gut microbial community, is a recurring theme, often contributing to a state of chronic low-grade inflammation that characterizes obesity [2]. This inflammatory response is not merely a consequence but an active driver, modulated by specific microbial taxa and their metabolites which interact with the host immune system and metabolic processes [2]. Beyond inflammation, gut microbes are actively involved in crucial metabolic functions, including the efficiency of nutrient extraction, the precise regulation of host energy balance, and overall immune modulation [3].

A significant aspect of this interaction is the role of diet. Dietary patterns are powerful modulators of gut microbial composition and function, directly impacting how the gut microbiota influences host energy harvest, insulin sensitivity, and inflammatory responses [4]. This means that dietary interventions are not just about caloric intake but also about shaping a beneficial microbial environment. One of the most critical metabolic products of the gut microbiota are Short-Chain Fatty Acids (SCFAs), such as acetate, propionate, and butyrate [5]. These SCFAs are not mere byproducts but active signaling molecules that influence host energy metabolism, satiety signals, the reinforcement of gut barrier function, and the intricate regulation of inflammation. Their multifaceted actions underscore their potential as key therapeutic targets in the battle against obesity [5].

Given the central role of the gut microbiota, a range of targeted therapeutic strategies are under intense investigation. These include personalized dietary modifications designed to cultivate a healthier microbial profile, the judicious use of probiotics (live beneficial microorganisms) and prebiotics (non-digestible compounds that promote beneficial microbial growth), and the synergistic combination of both in synbiotics [3, 7]. These interventions aim to favorably modulate the gut microbiota, leading to improvements in metabolic health, aiding in weight management, and reducing systemic inflammation [7]. Furthermore, more advanced and direct interventions like Fecal Microbiota Transplantation (FMT) are being explored as a promising method to combat obesity by re-establishing a healthier, balanced gut microbiome in dysbiotic individuals [6]. Preclinical and clinical studies are actively evaluating FMT's efficacy in promoting weight loss, improving metabolic parameters, and normalizing gut microbial composition in obese patients [6].

The influence of the gut microbiota extends beyond local gut function, engaging in complex bidirectional communication with the central nervous system through what is known as the gut microbiota-brain axis [8]. This axis plays a significant regulatory role in obesity by influencing critical neurological processes that govern appetite, satiety signaling, overall energy expenditure, and even mood. Understanding these communication pathways offers new insights into the neurobiological underpinnings of weight gain and provides novel targets for intervention strategies aimed at obesity management [8]. A comprehensive review of these diverse gut microbiota-targeted therapies, encompassing dietary approaches, probiotics, prebiotics, synbiotics, FMT, and even pharmacological interventions, is essential to critically evaluate their mechanisms, clinical efficacy, and future potential in managing the complexities of obesity and metabolic syndrome [9].

Finally, the foundational establishment of the gut microbiota early in life is increasingly recognized as a determinant of future metabolic health [10]. Factors such as the mode of birth (vaginal delivery versus C-section), infant feeding practices (breastfeeding versus formula feeding), and early-life exposure to antibiotics profoundly shape the initial development of the infant microbiome. These early influences contribute to long-term metabolic programming, ultimately affecting an individual's susceptibility to weight gain and the development of obesity later in life [10]. This highlights the importance of early life interventions in preventing obesity.

Conclusion

The gut microbiota plays a crucial and multifaceted role in the pathogenesis of obesity and metabolic syndrome. Dysbiosis in this microbial community contributes significantly to chronic low-grade inflammation, a key characteristic of obesity, by modulating host immune responses and energy metabolism. Gut microbes influence host metabolism through processes such as nutrient extraction, energy regulation, and immune modulation. Dietary patterns are particularly impactful, reshaping the gut microbial composition and function, thereby affecting host energy harvest, insulin sensitivity, and inflammatory responses. Short-Chain Fatty Acids (SCFAs), produced by the gut microbiota, emerge as vital mediators, influencing energy metabolism, satiety, gut barrier integrity, and inflammation, positioning them as potential therapeutic targets. Various interventions aim to modulate the gut microbiota, including dietary modifications, prebiotics, probiotics, synbiotics, and Fecal Microbiota Transplantation (FMT). These strategies demonstrate potential in improving metabolic health, managing weight, and reducing inflammation. The gut microbiota-brain axis also contributes significantly by regulating appetite, satiety, energy expenditure, and mood, offering new avenues for obesity management. Furthermore, early-life factors like birth mode, infant feeding, and antibiotic exposure shape the infant microbiome, influencing long-term metabolic programming and obesity susceptibility. These insights collectively underscore the gut microbiota as a critical player and a promising target for preventing and treating obesity and metabolic syndrome.

References

1.    
2. Meng-Xi H, Xin-Xin Y, Yan-Ni F (2023) .Nutrients 15:2147.        

   , ,

3.    
4. Daniel MR, Andrea AEAvdM, Koen JPMdK (2023) .Nutrients 15:545.        

   , ,

5.    
6. Hao-Ran W, Yu-Hao M, Xiang-Yang L (2022) .J Clin Lab Anal 36:e24584.        

   , ,

7.    
8. Marwa SK, Fatemeh K, Zeinab K (2023) .World J Diabetes 14:1219-1240.        

   , ,

9.    
10. Yu-Ying Z, Ling-Zi L, Jun-Feng W (2024) .Cell Death Discov 10:26.        

    , ,

11.    
12. Fang Y, Bing-Qing X, Jing-Yuan C (2022) .Front Cell Infect Microbiol 12:955729.        

    , ,

13.    
14. Kuan-Yu L, Ying-Chen C, Tzu-Lung C (2023) .Int J Mol Scl 24:3968.        

    , ,

15.    
16. Ling-Jing S, Xiao-Ling L, Bo L (2023) .World J Clin Cases 11:3093-3105.        

    , ,

17.    
18. Yu-Hang Z, Xiao-Hui Y, Jin-Fang M (2023) .Nutrients 15:4247.        

    , ,

19.    
20. Xiaocui L, Huijie Z, Qian Y (2022) .Front Pediatr 10:846559.        

    , ,